Home › Research › Health systems and care delivery
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights
Jovalekic Aleksandar, Bullich Santiago, Roé-Vellvé Núria, Kolinger Guilherme Domingues, Howard Lorelei R, Elsholz Floriana, Lagos-Quintana Mariana, Blanco-Rodriguez Beatriz et al.. Pharmaceuticals (Basel, Switzerland), 2025-01-08
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. Initially, the clinical adoption of FBB PET faced significant barriers, including reimbursement challenges and uncertainties regarding its integration into diagnostic clinical practice. This review examines the progress made in overcoming these obstacles and describes the concurrent evolution of the diagnostic landscape. Advances in quantification methods have further strengthened the traditional visual assessment approach. Over the past decade, compelling evidence has emerged, demonstrating that amyloid PET has a strong impact on AD diagnosis, management, and outcomes across diverse clinical scenarios, even in the absence of amyloid-targeted therapies. Amyloid PET imaging has become essential in clinical trials and the application of new AD therapeutics, particularly for confirming eligibility criteria (i.e., the presence of amyloid plaques) and monitoring biological responses to amyloid-lowering therapies. Since its approval, FBB PET has transitioned from a purely diagnostic tool aimed primarily at excluding amyloid pathology to a critical component in AD drug development, and today, it is essential in the diagnostic workup and therapy management of approved AD treatments.
What this study adds
Evidence grade: Low
This review describes a decade of experience with florbetaben amyloid PET, which is used to confirm amyloid plaques and monitor responses to amyloid-lowering therapies. It does not test any treatment, cure, or prevention for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Aleksandar, J., Santiago, B., Núria, R.-V., Domingues, K. G., Howard Lorelei, R., Floriana, E., et al. (2024). Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights. Pharmaceuticals (Basel, Switzerland). https://doi.org/10.3390/ph17121648
Vancouver
Aleksandar J, Santiago B, Núria R.-V, Domingues KG, Howard Lorelei R, Floriana E, et al. Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights. Pharmaceuticals (Basel, Switzerland). 2024. doi:10.3390/ph17121648. PMID: 39770490.
BibTeX
@article{aleksandar2024-39770490,
author = {Aleksandar, Jovalekic and Santiago, Bullich and Núria, Roé-Vellvé and Domingues, Kolinger Guilherme and Howard Lorelei, R. and Floriana, Elsholz and Mariana, Lagos-Quintana and Beatriz, Blanco-Rodriguez and others},
title = {{Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights}},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2024},
doi = {10.3390/ph17121648},
pmid = {39770490},
url = {https://doi.org/10.3390/ph17121648}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Initially, the clinical adoption of FBB PET faced significant barriers, including reimbursement challenges and uncertainties regarding its integration into diagnostic clinical practice.
Why it matters
This review describes a decade of experience with florbetaben amyloid PET, which is used to confirm amyloid plaques and monitor responses to amyloid-lowering therapies. It does not test any treatment, cure, or prevention for Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 34 of the 97 points we could judge it on, which is 35 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pharmaceuticals (Basel, Switzerland)) |
| Journal's citation record | 1 / 4 | Pharmaceuticals: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-17) |
| Citations per year | 1 / 5 | 1.8 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Norman Koglin: h-index 33 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39770490) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 34 of the 97 points we could judge it on is 35 out of 100. |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Health systems and care delivery from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.